^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CYP4B1 expression

i
Other names: CYP4B1, Cytochrome P450 Family 4 Subfamily B Member 1, Cytochrome P450, Family 4, Subfamily B, Polypeptide 1, Cytochrome P450, Subfamily IVB, Polypeptide 1, Cytochrome P450 4B1, Cytochrome P450-HP, CYPIVB1, Microsomal Monooxygenase, P-450HP
Entrez ID:
6d
Multi-omics reveal disturbance of glucose homeostasis in pregnant rats exposed to short-chain perfluorobutanesulfonic acid. (PubMed, Ecotoxicol Environ Saf)
In conclusion, our results suggest that gestational exposure to PFBS may induce molecular perturbations in glucose homeostasis. These findings provide insights into the potential mechanisms contributing to the heightened risk of abnormal glucose tolerance associated with PFBS exposure.
Preclinical • Journal
|
GSTM1 (Glutathione S-transferase mu 1)
|
CYP4B1 expression
2ms
Cytochrome P450 genes expression in human prostate cancer. (PubMed, Mol Genet Metab Rep)
Therefore, the expression of CYPs is not directly associated with prostate cancer but is largely determined by genetic, epigenetic factors, as well as endogenous substrates and xenobiotics. The significant correlative relationship between CYPs and genes associated with cancer may indicate common regulatory pathways that may have a synergistic effect on the tumor, ensuring the survival of cancer cells.
Journal
|
ACTA2 (Actin Alpha 2 Smooth Muscle) • CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1) • IRF1 (Interferon Regulatory Factor 1) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • CXCL14 (C-X-C Motif Chemokine Ligand 14) • CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1) • CYP27A1 (Cytochrome P450 Family 27 Subfamily A Member 1) • CYP2R1 (Cytochrome P450 Family 2 Subfamily R Member 1) • VDR (Vitamin D Receptor)
|
IRF1 expression • CYP17A1 expression • CYP4B1 expression
3ms
Annona Muricata L. extract restores renal function, oxidative stress, immunohistochemical structure, and gene expression of TNF-α, IL-β1, and CYP2E1 in the kidney of DMBA-intoxicated rats. (PubMed, Front Pharmacol)
Conclusively, GRV is a natural medicinal product that can alleviate the renal injury resulting from environmental exposure to DMBA. The reno-protective effects of GRV may involve its anti-inflammatory and/or antioxidant properties, which are based on the presence of phytochemical compounds such as acetogenins, alkaloids, and flavonoids.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • CAT (Catalase)
|
CYP4B1 expression
3ms
Circ0087385 promotes DNA damage in benzo(a)pyrene-induced lung cancer development by upregulating CYP1A1. (PubMed, Toxicol Sci)
Interfering with CYP1A1 partially reversed the DNA damage induced by high expression of circ0087385, as well as decreased the level of BPDE and BPDE-DNA adducts. These findings provide novel insights into the interaction between epigenetics and genetics in chemical carcinogenesis which are crucial for understanding the epigenetic and genetic toxicity of chemicals.
Journal
|
CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1)
|
CYP4B1 expression
5ms
Therapeutic Effects of In Vivo Administration of An Inhibitor of Tryptophan 2,3-dioxygenase (680C91) for the Treatment of Fibroids: A Preclinical Study. (PubMed, Fertil Steril)
The results indicate that correction of aberrant tryptophan catabolism in fibroids could be an effective treatment through its effect to reduce cell proliferation and ECM accumulation.
Preclinical • Journal
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • CASP3 (Caspase 3) • CDK2 (Cyclin-dependent kinase 2) • TGFB1 (Transforming Growth Factor Beta 1) • TDO2 (Tryptophan 2,3-Dioxygenase) • CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1) • E2F1 (E2F transcription factor 1)
|
CYP4B1 expression • TDO2 overexpression
6ms
Quantitative analysis of the UDP-glucuronosyltransferase transcriptome in human tissues. (PubMed, Pharmacol Res Perspect)
Our results also revealed coexpression of the UGTs, Cytochrome P450s, and many transcription factors in the liver, suggesting potential coregulation or functional coordination. Our results provide the groundwork for future studies to detail further the regulation of the expression and activity of the UGTs.
Journal
|
UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • UGT1A9 (UDP Glucuronosyltransferase Family 1 Member A9)
|
CYP4B1 expression
6ms
Nrf2 Regulates the Expression of CYP2D6 by Inhibiting the Activity of Krüppel-Like Factor 9 (KLF9). (PubMed, Curr Drug Metab)
Our work revealed the inhibitory role of Nrf2 in regulating CYP2D6 expression. Moreover, Nrf2- dependent regulation of CYP2D6 can be used as a prognostic factor and therapeutic strategy in PD and liver cancer.
Journal
|
CYP2D6 (Cytochrome P450 Family 2 Subfamily D Member 6)
|
CYP4B1 expression
7ms
CYP1A1 immunohistochemistry is highly specific for angiofibroma of soft tissue among morphological mimics. (PubMed, Histopathology)
These findings confirm that CYP1A1 is 70% sensitive, consistent with the prevalence of AHRR::NCOA2 fusions that up-regulate this protein, and that it is highly specific among morphological mimics.
Journal
|
CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1) • NCOA2 (Nuclear Receptor Coactivator 2)
|
CYP4B1 expression
8ms
Altered Gene Expression of Cytochrome P450 and ABC Transporter in Human Hepatocellular Carcinoma HepG2 Cells Exposed to Bardoxolone Methyl. (PubMed, Drug Res (Stuttg))
BX had no significant effect on the expression of mRNAs for CYP2C9 and CYP2C19 in HepG2 cells. In conclusion, this study demonstrated that the gene expression of several CYPs and ABC transporters in HepG2 cells was altered when exposed to BX, suggesting the need to pay careful attention to drug-drug interactions in patients receiving BX for CKD treatment.
Journal
|
ABCC1 (ATP Binding Cassette Subfamily C Member 1) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
CYP4B1 expression
8ms
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. (PubMed, Nat Cancer)
The persistence of GATA6 and KRT17 cells post-CTX was significantly associated with poor survival after mFOLFIRINOX (mFFX), but not gemcitabine (GEM), treatment. Analysis of organoid models derived from chemo-naive and post-CTX samples demonstrated that CYP3A expression is a predictor of chemotherapy response and that CYP3A-expressing drug detoxification pathways can metabolize the prodrug irinotecan, a constituent of mFFX. These findings identify CYP3A-expressing drug-tolerant cell phenotypes in residual disease that may ultimately inform adjuvant treatment selection.
Journal
|
GATA6 (GATA Binding Protein 6) • KRT17 (Keratin 17)
|
CYP4B1 expression
|
gemcitabine • irinotecan
10ms
ABCB11 accumulated in immature tertiary lymphoid structures participates in xenobiotic metabolic process and predicts resistance to PD-1/PD-L1 inhibitors in head and neck squamous cell carcinoma. (PubMed, Transl Oncol)
Whole slide scans of 110 HNSCC tissues with hematoxylin-eosin (HE) and multispectral immuno-fluorescent (mIF) staining revealed that ABCB11 had a high co-expression with CYP1A2 in immature TLSs, and colocalization of ABCB11 and CYP1A2 in immature TLs significantly associated with high infiltration of immunosuppressive T-regulatory (Treg). Our study revealed that ABCB11 accumulated in immature TLSs might upregulate CYP1A2 to mediate xenobiotic metabolic process, thus increase the immunosuppressive Treg infiltration, and induce resistance to PD-1/PD-L1 inhibitors in HNSCC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2)
|
CYP4B1 expression
11ms
Targeting cytochrome P450-expressing breast cancer cells for selective activation of duocarmycin bioprecursors (EACR 2023)
LCMS confirmed the presence of hydroxylated seco-duocarmycins, and structure-activity relationship studies revealed that subtle changes to the substitution pattern of the DNA recognition motif resulted in changes to the CYP bioactivation and chemosensitivity. The duocarmycin bio precursors were intolerant by functionalization at selected positions on the DNA binding motif while position 5 was critical for potent bioactivation and anticancer activity.ConclusionModifications to the structure of the seco-duocarmycins influence the extent of their CYP-mediated activation and indicate their potential for breast cancer chemotherapy.
PARP Biomarker
|
CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1)
|
CYP4B1 expression
11ms
Tumour extracellular vesicles and particles induce liver metabolic dysfunction. (PubMed, Nature)
Notably, tumour EVP education enhanced side effects of chemotherapy, including bone marrow suppression and cardiotoxicity, suggesting that metabolic reprogramming of the liver by tumour-derived EVPs may limit chemotherapy tolerance in patients with cancer. Our results reveal how tumour-derived EVPs dysregulate hepatic function and their targetable potential, alongside TNF inhibition, for preventing fatty liver formation and enhancing the efficacy of chemotherapy.
Journal
|
RAB27A (RAB27A, Member RAS Oncogene Family)
|
CYP4B1 expression
12ms
Hepatic nuclear factor 4 alpha promotes the ferroptosis of lung adenocarcinoma via transcriptional activation of cytochrome P450 oxidoreductase. (PubMed, PeerJ)
We found that HNF4A expression significantly decreased in the ferroptosis of A549 cells, and this change can be blocked by deferoxamine, an inhibitor of ferroptosis...Restoration of POR expression blocked the promoting effect of HNF4A on ferroptosis in lung adenocarcinoma. HNF4A promotes POR expression through binding to the POR's promoter, and subsequently promotes the ferroptosis of lung adenocarcinoma.
Journal
|
HNF1A (HNF1 Homeobox A) • POR (Cytochrome P450 Oxidoreductase)
|
CYP4B1 expression
1year
Redox Proteomic Profile of Tirapazamine-Resistant Murine Hepatoma Cells. (PubMed, Int J Mol Sci)
These data support the fact that the main mechanism of action of TPZ under aerobic conditions is oxidative stress. The unchanged expression of intranuclear antioxidant proteins peroxiredoxin, glutaredoxin, and glutathione peroxidase, and a modest increase in the expression of DNA damage repair proteins, tend to support non-site-specific but not intranuclear oxidative stress as a main factor of TPZ aerobic cytotoxicity.
Preclinical • Journal
|
GLRX (Glutaredoxin) • CAT (Catalase)
|
CYP4B1 expression
|
Tirazone (tirapazamine)
over1year
Effects of β-eudesmol and atractylodin on target genes and hormone related to cardiotoxicity, hepatotoxicity, and endocrine disruption in developing zebrafish embryos. (PubMed, Sci Prog)
While β-eudesmol did not alter the expression of the cytochrome P450 family 1 subfamily A member 1 gene, atractylodin at high concentrations upregulated the gene, suggesting its potential enzyme-inducing activity in this gene. β-eudesmol, but not atractylodin, showed some stress-reducing properties with suppression of cortisol production.
Journal
|
CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1) • FABP1 (Fatty Acid Binding Protein 1)
|
CYP4B1 expression
over1year
Bisphenol A is a carcinogen that induces lipid accumulation, peroxisome proliferator‑activated receptor‑γ expression and liver disease. (PubMed, Exp Ther Med)
Downregulated CYP1A1 and CYP1B1 gene expression implied that BPA-treated THLE-2 cells decreased capacity for carcinogen metabolism, while upregulated CYP2S1 gene expression exerted minimal cytotoxicity. The present study revealed that BPA served as a carcinogen, enhanced tumorigenesis susceptibility and may induce other types of liver disease.
Journal
|
CLU (Clusterin) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1) • CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
|
CYP4B1 expression
over1year
Suppression of colonic oxidative stress caused by chronic ethanol administration and attenuation of ethanol-induced colitis and gut leakiness by oral administration of sesaminol in mice. (PubMed, Food Funct)
Moreover, it prevented the chronic ethanol-induced gut leakiness by restoring tight junction proteins, giving rise to lower plasma endotoxin levels compared with those of ethanol-administered mice. All of these results suggest that dietary supplementation of sesaminol may lower the risk of ER-CRC by suppressing each of the above-mentioned steps in ER-CRC pathogenesis.
Preclinical • Journal
|
IL6 (Interleukin 6) • HMOX1 (Heme Oxygenase 1) • CCL2 (Chemokine (C-C motif) ligand 2)
|
HMOX1 expression • CYP4B1 expression
over1year
Establishment and Characterization of Novel Human Intestinal In Vitro Models for Absorption and First-Pass Metabolism Studies. (PubMed, Int J Mol Sci)
This study revealed that the human cell lines HROC183 T0 M2 and HROC217 T1 M2 may be better suited models and possess higher predictive power of pregnane X receptor- and vitamin D-mediated drug metabolism than Caco-2 cells. Consequently, they represent useful tools for predicting intestinal absorption and simultaneously enable assessment of membrane permeability and first-pass metabolism.
Preclinical • Journal
|
CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
CYP4B1 expression